Quantity Add to cart Inquiry
| Product Name | Biotinylated Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer |
| Cat. No. | MHCRP-0382 |
| Category | Proteins & Peptides |
| Product Description | Recombinant Biotinylated Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*02:01),Ile21-Met119 (B2M) and LMLGEFLKL peptide. |
| Size | 100/500 μg |
| Format | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Storage | Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Shipping Temp | Shipped at ambient temperature. |
| Lead Time | Product delivery time depends on the supplier. |
| Species | Human |
| Expression Host | HEK293 |
| Accession No | A0A140T913(HLA-A*02:01)&P61769(B2M)&LMLGEFLKL |
| Tag | C-His-Avi |
| Tag Position | C-terminus |
| Molecular Type | Monomer |
| Molecular Weight (MV) | The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 55-63 kDa based on Bis-Tris PAGE result. |
| Gene Synonyms | Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha |
| Purity | > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC. |
| Amino Acid Range | Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M), and LMLGEFLKL peptide |
| Activity | Immobilized biotinylated human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) monomer, His tag at 1 μg/mL (100 μL/well) on streptavidin (5 μg/mL) precoated plate. Dose response curve for anti-B2M antibody, mFc tag with the EC50 of 13.6 ng/mL determined by ELISA (QC Test). |
| Product Background | Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. |
| Allele | HLA-A*02:01 |
| Biotinylated | Yes |
Tel:
One-stop service